A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8)
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
This is a four-part dose-escalation and confirmation study in participants with advanced
solid tumors. Part A is for dose escalation and determination of maximum tolerated dose (MTD)
and recommended Phase 2 dose (RP2D) of MK-4827. Part B is a prostate/ovarian cancer cohort
expansion. Part C is for a cohort of participants with relapsed or refractory T-cell
prolymphocytic leukemia (T-PLL) or chronic lymphocytic leukemia (CLL). Part D will be for a
cohort of participants with locally advanced or metastatic colorectal carcinoma (CRC),
persistent or recurrent endometrial carcinoma, locally advanced or metastatic triple negative
or highly proliferative estrogen receptor positive (ER+) breast cancer, or partially
platinum-sensitive epithelial ovarian cancer. The study is also designed to find out whether
MK-4827 causes at least 50% inhibition of poly adenosine diphosphate ribose polymerase (PARP)
enzyme activity.